Beijing, China – 16 Sep 2026 – The Center for Medical Device Evaluation (CMDE) of China’s National Medical Products Administration (NMPA) announced a public consultation on the revised draft guideline, Guidelines for Registration and Review of Mycobacterium tuberculosis Complex Resistance Gene Mutation Detection Reagents (2026 Revised Edition) (Draft for Comments), aimed at standardizing technical review requirements and guiding registration applicants in preparing submission dossiers, with feedback due by 15 October 2026.
Consultation Snapshot
| Item | Detail |
|---|---|
| Agency | CMDE, under the National Medical Products Administration (NMPA), China |
| Action | Public solicitation of opinions on a revised draft registration review guideline |
| Document | Guidelines for Registration and Review of Mycobacterium tuberculosis Complex Resistance Gene Mutation Detection Reagents (2026 Revised Edition, Draft for Comments) |
| Purpose | Standardize technical review requirements; guide applicants in preparing and writing registration dossiers |
| Notice Date | 16 September 2026 |
| Comment Deadline | 15 October 2026, via email using the prescribed feedback form and subject‑line naming convention |
| Original Notice | cmde.org.cn (published 16 September 2026) |
Guideline Scope & Submission Channels
- Product Scope: The guideline covers in vitro diagnostic reagents that detect resistance‑associated gene mutations in the Mycobacterium tuberculosis complex — molecular tests used to identify drug‑resistant TB (including multidrug‑resistant TB) directly from clinical specimens, in contrast to slower culture‑based drug susceptibility testing.
- Revision, Not First Edition: CMDE has revised the existing guideline rather than issuing an inaugural document, indicating updates to review expectations accumulated from prior registration experience. The specific changes were not disclosed in the notice; the full draft is available for download from CMDE.
- Submission Format: Comments must be filed via the official feedback form (Annex 2) by email, with subject lines and file names formatted as “Guideline name – feedback + organization name.”
- Contacts: Cheng Xi, Liu Rongzhi (+86‑10‑86452580, +86‑10‑86452532; chengxi@cmde.org.cn, liurz@cmde.org.cn).
Sector Background
- Molecular Resistance Detection: Gene mutation assays — typically PCR‑based — identify resistance‑conferring mutations (e.g., in rpoB for rifampicin resistance) within hours, enabling rapid treatment decisions versus weeks for phenotypic testing.
- Public Health Priority: China remains among the countries with the highest TB and multidrug‑resistant TB burden globally, making fast, accurate resistance detection central to national TB control programs and the WHO End TB Strategy.
- IVD Registration Environment: CMDE technical review guidelines define the evidentiary expectations (analytical performance, clinical studies, reference comparators) for IVD registration in China; public consultation is the standard step before finalization.
Market Impact & Outlook
- Regulatory Predictability: A revised, codified standard reduces dossier ambiguity for IVD sponsors and shortens the review cycle for resistance‑detection assays targeting the M. tuberculosis complex.
- Competitive Landscape: Domestic molecular diagnostics developers — alongside global IVD players active in China’s TB testing market — should benchmark their clinical evidence and performance claims against the 2026 draft before launching new registrations or renewals.
- Portfolio Implications: Manufacturers with existing TB resistance‑detection products should assess whether current dossiers and performance data meet the revised expectations, particularly on mutation coverage and clinical concordance requirements.
- Participation Window: Stakeholders have until 15 October 2026 to influence the final guideline — an opportunity to raise practical issues on reference standards, comparator selection, and multi‑center clinical study design.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of the draft guideline, and its potential impact on in vitro diagnostic registration in China. The draft is subject to revision based on public feedback, and actual requirements, effective dates, and review outcomes may differ materially.-China Health Reform Pulse
Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916144510144.html